Towards the implementation of CYP2D6 and CYP2C19 genotypes in clinical practice: Update and report from a pharmacogenetic service clinic

References

• Adli, M., Bauer, M. & Rush, A.J. (2006). Algorithms and collaborative-care systems for depression: Are they effective and why? A systematic review. Biological Psychiatry, 59, 1029–1038.
   PubMed Web of Science ®Google Scholar
• Alenius, M., Wadelius, M., Dahl, M.L., Hartvig, P., Lindstrom, L. & Hammarlund-Udenaes, M. (2008). Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting. Journal of Psychiatric Research, 42, 884–893.
   PubMedGoogle Scholar
• Anderson, I.M., Nutt, D.J. & Deakin, J.F. (2000). Evidence- based guidelines for treating depressive disorders with antidepressants: A revision of the 1993 British Association for Psychopharmacology guidelines. British Association for Psychopharmacology.Journal of Psycopharmacology, 14, 3–20.
   PubMed Web of Science ®Google Scholar
• Azuma, J., Hasunuma, T., Kubo, M., Miyatake, M., Koue, T., Higashi, K., … Hara, S. (2012). The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine. European Journal of Clinical Pharmacology, 68, 29–37.
   PubMed Web of Science ®Google Scholar
• Barbui, C., Esposito, E. & Cipriani, A. (2009). Selective serotonin reuptake inhibitors and risk of suicide: A systematic review of observational studies. Canadian Medical Association Journal, 180, 291–297.
   PubMed Web of Science ®Google Scholar
• Bartecek, R., Jurica, J., Zrustova, J., Kasparek, T., Pindurova, E. & Zourkova, A. (2012). Relevance of CYP2D6 variability in first-episode schizophrenia patients treated with risperidone. Neuro Endocrinology Letters, 33, 236–244.
   PubMedGoogle Scholar
• Berwaerts, J., Cleton, A., Herben, V., van de Vliet, I., Chang, I., van Hoek, P. & Eerdekens, M. (2009). The effects of paroxetine on the pharmacokinetics of paliperidone extended-release tablets. Pharmacopsychiatry, 42, 158–163.
   PubMed Web of Science ®Google Scholar
• Bigos, K.L., Bies, R.R., Pollock, B.G., Lowy, J.J., Zhang, F. & Weinberger, D.R. (2011). Genetic variation in CYP3A43 explains racial difference in olanzapine clearance. Molecular Psychiatry, 16, 620–625.
   PubMed Web of Science ®Google Scholar
• Bijl, M.J., Visser, L.E., Hofman, A., Vulto, A.G., van Gelder, T., Stricker, B.H. & van Schaik, R.H. (2008). Influence of the CYP2D6*4 polymorphism on dose, switching and discontinuation of antidepressants. British Journal of Clinical Pharmacology, 65, 558–564.
   PubMed Web of Science ®Google Scholar
• Bishop, J.R., Ellingrod, V.L., Akroush, M. & Moline, J. (2009). The association of serotonin transporter genotypes and selective serotonin reuptake inhibitor (SSRI)-associated sexual side effects: Possible relationship to oral contraceptives. Human Psychopharmacology, 24, 207–215.
   PubMed Web of Science ®Google Scholar
• Bondolfi, G., Morel, F., Crettol, S., Rachid, F., Baumann, P. & Eap, C.B. (2005). Increased clozapine plasma concentrations and side effects induced by smoking cessation in 2 CYP1A2 genotyped patients. Therapeutic Drug Monitoring, 27, 539–543.
   PubMed Web of Science ®Google Scholar
• Brandl, E.J., Tiwari, A.K., Zhou, X., Deluce, J., Kennedy, J.L., Müller, D.J. & Richter, M.A. (2013). Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder. Pharmacogenomics Journal. doi: 10.1038/tpj.2013.12
   PubMedGoogle Scholar
• Brockmöller, J., Meineke, I. & Kirchheiner, J. (2007). Pharmacokinetics of mirtazapine: Enantioselective effects of the CYP2D6 ultra rapid metabolizer genotype and correlation with adverse effects. Clinical Pharmacology and Therapeutics, 81, 699–707.
   PubMed Web of Science ®Google Scholar
• Bromet, E., Andrade, L.H., Hwang, I., Sampson, N.A., Alonso, J., de Girolamo, G., … Kessler, R.C. (2011). Cross-national epidemiology of DSM-IV major depressive episode. BMC Medicine, 9, 90.
   PubMed Web of Science ®Google Scholar
• Calarge, C.A. & Miller, D.D. (2011). Predictors of risperidone and 9-hydroxyrisperidone serum concentration in children and adolescents. Journal of Child and Adolescent Psychopharmacology, 21, 163–169.
   PubMedGoogle Scholar
• Crescenti, A., Mas, S., Gasso, P., Parellada, E., Bernardo, M. & Lafuente, A. (2008). Cyp2d6*3, *4, *5 and *6 polymorphisms and antipsychotic-induced extrapyramidal side-effects in patients receiving antipsychotic therapy. Clinical and Experimental Pharmacology and Physiology, 35, 807–811.
   PubMed Web of Science ®Google Scholar
• de Vos, A., van der Weide, J. & Loovers, H.M. (2011). Association between CYP2C19*17 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patients. Pharmacogenomics Journal, 11, 359–367.
   PubMed Web of Science ®Google Scholar
• Dorado, P., Peñas-LLedó, E.M., de la Rubia, A. & LLerena, A. (2009). Relevance of CYP2D6 -1584C> G polymorphism for thioridazine:mesoridazine plasma concentration ratio in psychiatric patients. Pharmacogenomics, 10, 1083–1089.
   PubMed Web of Science ®Google Scholar
• Dunbar, L., Miles, W., Wheeler, A., Sheridan, J., Pulford, J. & Butler, R. (2009). The CYP2D6 metaboliser status of patients prescribed risperidone for the treatment of psychosis. New Zealand Medical Journal, 122, 29–34.
   PubMedGoogle Scholar
• Fleeman, N., Dundar, Y., Dickson, R., Jorgensen, A., Pushpakom, S., McLeod, C., … Walley, T. (2011). Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: Systematic review and meta-analyses. Pharmacogenomics Journal, 11, 1–14.
   PubMed Web of Science ®Google Scholar
• Gex-Fabry, M., Eap, C.B., Oneda, B., Gervasoni, N., Aubry, J.M., Bondolfi, G. & Bertschy, G. (2008). CYP2D6 and ABCB1 genetic variability: Influence on paroxetine plasma level and therapeutic response. Therapeutic Drug Monitoring, 30, 474–482.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Tejera, G.M. & Corey, S. (2009). CYP2D6 genotypes in Puerto Rican psychiatry patients with intolerance of antidepressants and antipsychotics. Boletin de la Asociacion Medica de Puerto Rico, 101, 7–12.
   PubMedGoogle Scholar
• Gunes, A., Spina, E., Dahl, M.L. & Scordo, M.G. (2008). ABCB1 polymorphisms influence steady-state plasma levels of 9-hydroxyrisperidone and risperidone active moiety. Therapeutic Drug Monitoring, 30, 628–633.
   PubMed Web of Science ®Google Scholar
• Gvozdic, K., Brandl, E.J., Taylor, D.L. & Müller, D.J. (2012). Genetics and personalized medicine in antidepressant treatment. Current Pharmaceutical Design, 18, 5853–5878.
   PubMedGoogle Scholar
• Hall-Flavin, D.K., Winner, J.G., Allen, J.D., Jordan, J.J., Nesheim, R.S., Snyder, K.A., … Mrazek, D.A. (2012). Using a pharmacogenomic algorithm to guide the treatment of depression. Translational Psychiatry, 2, e172.
   PubMed Web of Science ®Google Scholar
• Hendset, M., Haslemo, T., Rudberg, I., Refsum, H. & Molden, E. (2006). The complexity of active metabolites in therapeutic drug monitoring of psychotropic drugs. Pharmacopsychiatry, 39, 121–127.
   PubMed Web of Science ®Google Scholar
• Hendset, M., Molden, E., Refsum, H. & Hermann, M. (2009). Impact of CYP2D6 genotype on steady-state serum concentrations of risperidone and 9-hydroxyrisperidone in patients using long-acting injectable risperidone. Journal of Clinical Psychopharmacology, 29, 537–541.
   PubMed Web of Science ®Google Scholar
• Herbild, L., Bech, M., Gyrd-Hansen, D., Christensen, M., Werge, T. & Nielsen, K.A. (2011). Do guidelines recommending pharmacogenetic testing of psychiatric patients affect treatment costs and the use of healthcare services?Scandinavian journal of public health39, 147–155.
   PubMedGoogle Scholar
• Hicks, J.K., Swen, J.J., Thorn, C.F., Sangkuhl, K., Kharasch, E.D., Ellingrod, V.L., … Stingl, J.C. (2013). Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clinical pharmacology and therapeutics, 93, 402–408.
   PubMed Web of Science ®Google Scholar
• Huezo-Diaz, P., Perroud, N., Spencer, E.P., Smith, R., Sim, S., Virding, S., … Aitchison, K.J. (2012). CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP. Journal of Psycopharmacology, 26, 398–407.
   PubMed Web of Science ®Google Scholar
• Ishak, K.J., Tan, Y., Glass, J., Luong, D. & Caro, J.J. (2008). Risk of discontinuation of risperidone after exposure to potentially interacting drugs: A nested case-control study in patients with schizophrenia. Clinical Therapeutics, 30, 1251–1263.
   PubMedGoogle Scholar
• Jaquenoud Sirot, E., Knezevic, B., Morena, G.P., Harenberg, S., Oneda, B., Crettol, S., … Eap, C.B. (2009). ABCB1 and cytochrome P450 polymorphisms: Clinical pharmacogenetics of clozapine. Journal of Clinical Psychopharmacology, 29, 319–326.
   PubMed Web of Science ®Google Scholar
• Jin, Y., Pollock, B.G., Frank, E., Cassano, G.B., Rucci, P., Müller, D.J., … Bies, R.R. (2010). Effect of age, weight, and CYP2C19 genotype on escitalopram exposure. Journal of Clinical Pharmacology, 50, 62–72.
   PubMed Web of Science ®Google Scholar
• Jovanovic, N., Bozina, N., Lovric, M., Medved, V., Jakovljevic, M. & Peles, A.M. (2010). The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naive patients with first-episode schizophrenia treated with risperidone. European Journal of Clinical Pharmacology, 66, 1109–1117.
   PubMed Web of Science ®Google Scholar
• Jürgens, G., Rasmussen, H.B., Werge, T., Dalhoff, K., Nordentoft, M. & Andersen, S.E. (2012). Does the medication pattern reflect the CYP2D6 genotype in patients with diagnoses within the schizophrenic spectrum?Journal of Clinical Psychopharmacology, 32, 100–105.
   PubMedGoogle Scholar
• Kang, R.H., Jung, S.M., Kim, K.A., Lee, D.K., Cho, H.K., Jung, B.J., Kim, Y.K., Kim, S.H., Han, C., Lee, M.S. & Park, J.Y. (2009). Effects of CYP2D6 and CYP3A5 genotypes on the plasma concentrations of risperidone and 9-hydroxyrisperidone in Korean schizophrenic patients. J Clin Psychopharmacol, 29, 272–277.
   PubMed Web of Science ®Google Scholar
• Kandasamy, M., Srinivas, P., Subramaniam, K., Ravi, S., John, J., Shekar, R., … Thangam, S. (2010). Differential outcomes from metabolic ratios in the identification of CYP2D6 phenotypes – Focus on venlafaxine and O-desmethylvenlafaxine. European Journal of Clinical Pharmacology, 66, 879–887.
   PubMed Web of Science ®Google Scholar
• Kim, J.R., Seo, H.B., Cho, J.Y., Kang, D.H., Kim, Y.K., Bahk, W.M., … Jang, I.J. (2008). Population pharmacokinetic modelling of aripiprazole and its active metabolite, dehydroaripiprazole, in psychiatric patients. British Journal of Clinical Pharmacology, 66, 802–810.
   PubMed Web of Science ®Google Scholar
• Kobylecki, C.J., Jakobsen, K.D., Hansen, T., Jakobsen, I.V., Rasmussen, H.B. & Werge, T. (2009). CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients: A retrospective matched case-control study. Neuropsychobiology, 59, 222–226.
   PubMed Web of Science ®Google Scholar
• Kohlrausch, F.B., Gama, C.S., Lobato, M.I., Belmonte-de-Abreu, P., Callegari-Jacques, S.M., Gesteira, A., … Hutz, M.H. (2008). Naturalistic pharmacogenetic study of treatment resistance to typical neuroleptics in European-Brazilian schizophrenics. Pharmacogenetics and Genomics, 18, 599–609.
   PubMed Web of Science ®Google Scholar
• Kwadijk-de Gijsel, S., Bijl, M.J., Visser, L.E., van Schaik, R.H., Hofman, A., Vulto, A.G., … Ch Stricker, B.H. (2009). Variation in the CYP2D6 gene is associated with a lower serum sodium concentration in patients on antidepressants. British Journal of Clinical Pharmacology, 68, 221–225.
   PubMed Web of Science ®Google Scholar
• Lee, S.T., Ryu, S., Kim, S.R., Kim, M.J., Kim, S., Kim, J.W., … Hong, K.S. (2012). Association study of 27 annotated genes for clozapine pharmacogenetics: Validation of preexisting studies and identification of a new candidate gene, ABCB1, for treatment response. Journal of Clinical Psychopharmacology, 32, 441–448.
   PubMed Web of Science ®Google Scholar
• Lind, A.B., Reis, M., Bengtsson, F., Jonzier-Perey, M., Powell Golay, K., Ahlner, J., … Dahl, M.L. (2009). Steady-state concentrations of mirtazapine, N-desmethylmirtazapine, 8-hydroxymirtazapine and their enantiomers in relation to cytochrome P450 2D6 genotype, age and smoking behaviour. Clinical Pharmacokinetics, 48, 63–70.
   PubMed Web of Science ®Google Scholar
• Lobello, K.W., Preskorn, S.H., Guico-Pabia, C.J., Jiang, Q., Paul, J., Nichols, A.I., … Ninan, P.T. (2010). Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: A secondary analysis of 4 studies in major depressive disorder. Journal of Clinical Psychiatry, 71, 1482–1487.
   PubMed Web of Science ®Google Scholar
• Locatelli, I., Kastelic, M., Koprivsek, J., Kores-Plesnicar, B., Mrhar, A., Dolzan, V. & Grabnar, I. (2010). A population pharmacokinetic evaluation of the influence of CYP2D6 genotype on risperidone metabolism in patients with acute episode of schizophrenia. European Journal of Pharmaceutical Sciences, 41, 289–298.
   PubMed Web of Science ®Google Scholar
• Mannheimer, B., von Bahr, C., Pettersson, H. & Eliasson, E. (2008). Impact of multiple inhibitors or substrates of cytochrome P450 2D6 on plasma risperidone levels in patients on polypharmacy. Therapeutic Drug Monitoring, 30, 565–569.
   PubMed Web of Science ®Google Scholar
• Mas, S., Gasso, P., Alvarez, S., Parellada, E., Bernardo, M. & Lafuente, A. (2012). Intuitive pharmacogenetics: Spontaneous risperidone dosage is related to CYP2D6, CYP3A5 and ABCB1 genotypes. Pharmacogenomics Journal, 12, 255–259.
   PubMed Web of Science ®Google Scholar
• McAlpine, D.E., Biernacka, J.M., Mrazek, D.A., O’Kane, D.J., Stevens, S.R., Langman, L.J., … Moyer, T.P. (2011). Effect of cytochrome P450 enzyme polymorphisms on pharmacokinetics of venlafaxine. Therapeutic Drug Monitoring, 33, 14–20.
   PubMed Web of Science ®Google Scholar
• Mrazek, D.A. (2010). Psychiatric Pharmacogenomics. New York: Oxford University Press.
   Google Scholar
• Mrazek, D.A., Biernacka, J.M., O’Kane, D.J., Black, J.L., Cunningham, J.M., Drews, M.S., … Weinshilboum, R.M. (2011). CYP2C19 variation and citalopram response. Pharmacogenetics and Genomics, 21, 1–9.
   PubMed Web of Science ®Google Scholar
• Müller, D.J., Brandl, E.J., Hwang, R., Tiwari, A.K., Sturgess, J.E., Zai, C.C., … Richter, M.A. (2012). The AmpliChip(R) CYP450 test and response to treatment in schizophrenia and obsessive compulsive disorder: a pilot study and focus on cases with abnormal CYP2D6 drug metabolism. Genetic Testing and Molecular Biomarkers, 16, 897–903.
   PubMed Web of Science ®Google Scholar
• Müller, D.J., Chowdhury, N.I. & Zai, C.C. (2013). The pharmacogenetics of antipsychotic-induced adverse events. Current Opinion in Psychiatry, 26, 144–150.
   PubMed Web of Science ®Google Scholar
• Nagai, G., Mihara, K., Nakamura, A., Suzuki, T., Nemoto, K., Kagawa, S., … Kondo, T. (2012). Prolactin concentrations during aripiprazole treatment in relation to sex, plasma drugs concentrations and genetic polymorphisms of dopamine D2 receptor and cytochrome P450 2D6 in Japanese patients with schizophrenia. Psychiatry and Clinical Neurosciences, 66, 518–524.
   PubMed Web of Science ®Google Scholar
• Nichols, A.I., Focht, K., Jiang, Q., Preskorn, S.H. & Kane, C.P. (2011). Pharmacokinetics of venlafaxine extended release 75 mg and desvenlafaxine 50 mg in healthy CYP2D6 extensive and poor metabolizers: A randomized, open-label, two-period, parallel-group, crossover study. Clinical Drug Investigation, 31, 155–167.
   PubMed Web of Science ®Google Scholar
• Novalbos, J., Lopez-Rodriguez, R., Roman, M., Gallego- Sandin, S., Ochoa, D. & Abad-Santos, F. (2010). Effects of CYP2D6 genotype on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers. Journal of Clinical Psychopharmacology, 30, 504–511.
   PubMed Web of Science ®Google Scholar
• Nozawa, M., Ohnuma, T., Matsubara, Y., Sakai, Y., Hatano, T., Hanzawa, R., … Arai, H. (2008). The relationship between the response of clinical symptoms and plasma olanzapine concentration, based on pharmacogenetics: Juntendo University Schizophrenia Projects (JUSP). Therapeutic Drug Monitoring, 30, 35–40.
   PubMed Web of Science ®Google Scholar
• Parker, G., Rowe, M., Mehta, F. & Kumar, S. (2010). Will a new genotyping test help the clinician predict response to antidepressant drugs?Australasian Psychiatry, 18, 413–416.
   PubMed Web of Science ®Google Scholar
• Penas-Lledo, E.M., Blasco-Fontecilla, H., Dorado, P., Vaquero-Lorenzo, C., Baca-Garcia, E. & Llerena, A. (2012). CYP2D6 and the severity of suicide attempts. Pharmacogenomics, 13, 179–184.
   PubMed Web of Science ®Google Scholar
• Peters, E.J., Slager, S.L., Kraft, J.B., Jenkins, G.D., Reinalda, M.S., McGrath, P.J. & Hamilton, S.P. (2008). Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample. PloS One, 3, e1872.
   PubMed Web of Science ®Google Scholar
• Plesnicar, B.K. (2010). Personalized antipsychotic treatment: The adverse effects perspectives. Psychiatria Danubina, 22, 329–334.
   PubMed Web of Science ®Google Scholar
• Porcelli, S., Fabbri, C., Spina, E., Serretti, A. & De Ronchi, D. (2011). Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism. Expert Opinion On Drug Metabolism and Toxicology, 7, 1101–1115.
   PubMed Web of Science ®Google Scholar
• Rogers, H.L., Bhattaram, A., Zineh, I., Gobburu, J., Mathis, M., Laughren, T.P. & Pacanowski, M. (2012). CYP2D6 genotype information to guide pimozide treatment in adult and pediatric patients: basis for the U.S. Food and Drug Administration's new dosing recommendations. Journal of Clinical Psychiatry, 73, 1187–1190.
   PubMedGoogle Scholar
• Rudberg, I., Hermann, M., Refsum, H. & Molden, E. (2008a). Serum concentrations of sertraline and N-desmethyl sertraline in relation to CYP2C19 genotype in psychiatric patients. European Journal of Clinical Pharmacology, 64, 1181–1188.
   PubMed Web of Science ®Google Scholar
• Rudberg, I., Mohebi, B., Hermann, M., Refsum, H. & Molden, E. (2008b). Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients. Clinical Pharmacology and Therapeutics, 83, 322–327.
   PubMed Web of Science ®Google Scholar
• Rundell, J.R., Staab, J.P., Shinozaki, G., Saad-Pendergrass, D., Moore, K., McAlpine, D. & Mrazek, D. (2011). Pharmacogenomic testing in a tertiary care outpatient psychosomatic medicine practice. Psychosomatics, 52, 141–146.
   PubMed Web of Science ®Google Scholar
• Rush, A.J., Trivedi, M.H., Wisniewski, S.R., Stewart, J.W., Nierenberg, A.A., Thase, M.E., … Fava, M. (2006). Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. New England Journal of Medicine, 354, 1231–1242.
   PubMed Web of Science ®Google Scholar
• Schenk, P.W., van Fessem, M.A., Verploegh-Van Rij, S., Mathot, R.A., van Gelder, T., Vulto, A.G., … van Schaik, R.H. (2008). Association of graded allele-specific changes in CYP2D6 function with imipramine dose requirement in a large group of depressed patients. Molecular Psychiatry, 13, 597–605.
   PubMed Web of Science ®Google Scholar
• Schenk, P.W., van Vliet, M., Mathot, R.A., van Gelder, T., Vulto, A.G., van Fessem, M.A., … van Schaik, R.H. (2010). The CYP2C19*17 genotype is associated with lower imipramine plasma concentrations in a large group of depressed patients. Pharmacogenomics Journal, 10, 219–225.
   PubMedGoogle Scholar
• Serretti, A., Calati, R., Massat, I., Linotte, S., Kasper, S., Lecrubier, Y., … Souery, D. (2009). Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients. International Clinical Psychopharmacology, 24, 250–256.
   PubMed Web of Science ®Google Scholar
• Shapiro, D.A., Renock, S., Arrington, E., Chiodo, L.A., Liu, L.X., Sibley, D.R., … Mailman, R. (2003). Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology, 28, 1400–1411.
   PubMed Web of Science ®Google Scholar
• Sim, S.C., Nordin, L., Andersson, T.M., Virding, S., Olsson, M., Pedersen, N.L. & Ingelman-Sundberg, M. (2010). Association between CYP2C19 polymorphism and depressive symptoms. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics, 153B, 1160–1166.
   PubMed Web of Science ®Google Scholar
• Sistonen, J., Sajantila, A., Lao, O., Corander, J., Barbujani, G. & Fuselli, S. (2007). CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenetics and Genomics, 17, 93–101.
   PubMed Web of Science ®Google Scholar
• Skogh, E., Sjodin, I., Josefsson, M. & Dahl, M.L. (2011). High correlation between serum and cerebrospinal fluid olanzapine concentrations in patients with schizophrenia or schizoaffective disorder medicating with oral olanzapine as the only antipsychotic drug. Journal of Clinical Psychopharmacology, 31, 4–9.
   PubMed Web of Science ®Google Scholar
• Suzuki, T., Mihara, K., Nakamura, A., Nagai, G., Kagawa, S., Nemoto, K., … Kondo, T. (2011). Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia. Therapeutic Drug Monitoring, 33, 21–24.
   PubMed Web of Science ®Google Scholar
• Suzuki, Y., Fukui, N., Tsuneyama, N., Watanabe, J., Ono, S., Sugai, T., … Someya, T. (2012). Effect of the cytochrome P450 2D6*10 allele on risperidone metabolism in Japanese psychiatric patients. Human Psychopharmacology, 27, 43–46.
   PubMedGoogle Scholar
• Suzuki, Y., Sugai, T., Fukui, N., Watanabe, J., Ono, S., Inoue, Y., … Someya, T. (2011). CYP2D6 genotype and smoking influence fluvoxamine steady-state concentration in Japanese psychiatric patients: lessons for genotype-phenotype association study design in translational pharmacogenetics. Journal of Psycopharmacology, 25, 908–914.
   PubMed Web of Science ®Google Scholar
• Swen, J.J., Nijenhuis, M., de Boer, A., Grandia, L., Maitland-van der Zee, A.H., Mulder, H., … Guchelaar, H.J. (2011). Pharmacogenetics: from bench to byte – An update of guidelines. Clinical Pharmacology and Therapeutics, 89, 662–673.
   PubMed Web of Science ®Google Scholar
• Timmer, C.J., Sitsen, J.M. & Delbressine, L.P. (2000). Clinical pharmacokinetics of mirtazapine. Clinical Pharmacokinetics38, 461–474.
   PubMed Web of Science ®Google Scholar
• Tiwari, A.K., Souza, R.P. & Müller, D.J. (2009). Pharmacogenetics of anxiolytic drugs. Journal of Neural Transmission, 116, 667–677.
   PubMedGoogle Scholar
• Tsai, M.H., Lin, K.M., Hsiao, M.C., Shen, W.W., Lu, M.L., Tang, H.S., … Liu, Y.L. (2010). Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response. Pharmacogenomics, 11, 537–546.
   PubMed Web of Science ®Google Scholar
• Van Nieuwerburgh, F.C., Denys, D.A., Westenberg, H.G. & Deforce, D.L. (2009). Response to serotonin reuptake inhibitors in OCD is not influenced by common CYP2D6 polymorphisms. International Journal of Psychiatry in Clinical Practice, 13, 345–348.
   PubMed Web of Science ®Google Scholar
• Vetti, H.H., Molven, A., Eliassen, A.K. & Steen, V.M. (2010). Is pharmacogenetic CYP2D6 testing useful?Tidsskrift for den Norske Laegeforening, 130, 2224–2228.
   PubMedGoogle Scholar
• Waade, R.B., Christensen, H., Rudberg, I., Refsum, H. & Hermann, M. (2009). Influence of comedication on serum concentrations of aripiprazole and dehydroaripiprazole. Therapeutic Drug Monitoring, 31, 233–238.
   PubMed Web of Science ®Google Scholar
• Watanabe, J., Suzuki, Y., Fukui, N., Sugai, T., Ono, S., Inoue, Y. & Someya, T. (2008). Dose-dependent effect of the CYP2D6 genotype on the steady-state fluvoxamine concentration. Therapeutic Drug Monitoring, 30, 705–708.
   PubMed Web of Science ®Google Scholar
• Winner, J., Allen, J.D., Altar, C.A. & Spahic-Mihajlovic, A. (2013). Psychiatric pharmacogenomics predicts health resource utilization of outpatients with anxiety and depression. Translational Psychiatry, 3, e242.
   PubMed Web of Science ®Google Scholar
• Xiang, Q., Zhao, X., Zhou, Y., Duan, J.L. & Cui, Y.M. (2010). Effect of CYP2D6, CYP3A5, and MDR1 genetic polymorphisms on the pharmacokinetics of risperidone and its active moiety. Journal of Clinical Pharmacology, 50, 659–666.
   PubMedGoogle Scholar
• Yagihashi, T., Mizuno, M., Chino, B., Sato, Y., Sakuma, K., Takebayashi, T., … Kosaki, K. (2009). Effects of the CYP2D6*10 alleles and co-medication with CYP2D6-dependent drugs on risperidone metabolism in patients with schizophrenia. Human Psychopharmacology, 24, 301–308.
   PubMed Web of Science ®Google Scholar
• Yoo, H.D., Cho, H.Y., Lee, S.N., Yoon, H. & Lee, Y.B. (2012). Population pharmacokinetic analysis of risperidone and 9- hydroxyrisperidone with genetic polymorphisms of CYP2D6 and ABCB1. J Pharmacokinet Pharmacodyn, 39, 329–341.
   PubMedGoogle Scholar
• Zanger, U.M., Turpeinen, M., Klein, K. & Schwab, M. (2008). Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Analytical and Bioanalytical Chemistry, 392, 1093–1108.
   PubMed Web of Science ®Google Scholar
• Zhou, S.F., Liu, J.P. & Chowbay, B. (2009). Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metabolism Reviews, 41, 89–295.
   PubMed Web of Science ®Google Scholar